Generics in Europe

Date: January 4, 2016
Pages: 32
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G7B5D284989EN
Leaflet:

Download PDF Leaflet

Generics in Europe
INTRODUCTION

Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

HIGHLIGHTS
  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The European generics market is expected to generate total revenues of $57.4bn in 2015, representing a compound annual growth rate (CAGR) of 6.2% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 70.7% of total pharma volume in 2015.
  • The European market is dominated by markets with high generic uptake, including those in Western Europe, such as the UK and Germany, as well as those in Eastern Europe, such as Russia and Poland. However, markets such as France and Norway provide scope for the generics market to grow.
FEATURES
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Europe
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the Europe economy
KEY QUESTIONS ANSWERED
  • What was the size of the Europe generics market by value in 2015?
  • What will be the size of the Europe generics market in 2020?
  • What factors are affecting the strength of competition in the Europe generics market?
  • How has the market performed over the last five years?
  • How large is Europe’s generics market in relation to its regional counterparts?
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Europe generics market value: $ billion, 2011–15(e)
Table 2: Europe generics market volume: % of total pharma volume, 2011–15(e)
Table 3: Europe generics market geography segmentation: $ billion, 2015(e)
Table 4: Europe generics market value forecast: $ billion, 2015–20
Table 5: Europe generics market volume forecast: % of total pharma volume, 2015–20
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

LIST OF FIGURES

Figure 1: Europe generics market value: $ billion, 2011–15(e)
Figure 2: Europe generics market volume: % of total pharma volume, 2011–15(e)
Figure 3: Europe generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Europe generics market value forecast: $ billion, 2015–20
Figure 5: Europe generics market volume forecast: % of total pharma volume, 2015–20
Figure 6: Forces driving competition in the generics market in Europe, 2015
Figure 7: Drivers of buyer power in the generics market in Europe, 2015
Figure 8: Drivers of supplier power in the generics market in Europe, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2015
Figure 12: Mylan Inc.: revenues & profitability
Figure 13: Mylan Inc.: assets & liabilities
Figure 14: Sanofi SA: revenues & profitability
Figure 15: Sanofi SA: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Skip to top


Generics: Global Industry Guide US$ 1,270.75 Jan, 2016 · 252 pages
Generics in Scandinavia US$ 350.00 Jan, 2016 · 32 pages
Pharmacies US$ 1,400.00 May, 2015

Ask Your Question

Generics in Europe
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: